Advancing AFC in Neuromuscular Medicine: Program Launch & September Workshop
In 2025, the Royal College of Physicians and Surgeons of Canada granted approval for the National Training Standards for the Area of Focused Competence (AFC) in Neuromuscular Medicine thanks to the work by Drs. Erin O’Ferrall and Hernan Gonorazky. The AFC recognition builds upon a physician’s certification in a primary specialty through supplemental or advanced training/practice and offers the opportunity to recognize one’s enhanced competence (i.e. what we commonly refer to as subspecialty fellowship training) with an additional Royal College credential: DRCPSC.
This designation will help establish a national standard for training and specialist competence in Neuromuscular Medicine, support physicians in obtaining credentials that are recognized across Canada and internationally, and reduce fragmentation in training, care, and practice. By formalizing expertise in this focused area, it will also strengthen clinical capacity across the country.
With this approval, PGME offices can now apply for Royal College accreditation to offer AFC training programs in Neuromuscular Medicine that will be open to residents who have graduated from Neurology (adult or pediatric) or Physiatry residencies.
Our upcoming goal is to have 5 accredited AFC programs in Neuromuscular Medicine submit applications for accreditation to the Royal College by the end of 2026. To facilitate this goal, we will be hosting an AFC workshop at the upcoming annual NMD4C Investigator Meeting on September 25th, 2026.
If you are a neuromuscular or physiatry program director and would like to learn more or apply for accreditation, we’d like to hear from you!
Please consider attending September 25, 2026.
Register on the Event Page
- Read the Standards of Accreditation for Neuromuscular Medicine to see the program and site structural requirements.
- Review the Competency Portfolio Framework to view the clinical logs, de-identification guidelines, and milestone markers that fellows must complete.
Read next...
NMD4C Hosts 3rd Annual Basic Research Summer School at uOttawa!
From June 8 to 10, 2026, we hosted the 3rd annual NMD4C Basic Research Summer School at the University of Ottawa. The program supported 28 neuromuscular research trainees (graduate students and postdoctoral fellows) from across Canada and focused on developing practical skills, strengthening core knowledge in neuromuscular research, and providing opportunities to present and discuss their work. Through a combination of tutorials, lectures, hands-on workshops in cutting-edge wet lab techniques, flash talks, and both structured and informal networking, participants engaged with faculty, exchanged ideas, and built connections across institutions and career stages.
New Publication from the NMD4C Clinical Trial Network Strengthens Trial Capacity in Canada
We are pleased to share a new publication from the NMD4C Clinical Trial Network led by Kerri Lynn Schellenberg, Homira Osman, Maria Masnata, Rhiannon Hicks, Corinne Kagan, Ana Stosic, Stacey Lintern, Erin Beattie, Drs. Hanns Lochmüller, Craig Campbell, and Jean K Mah. This work focuses on the implementation of a coordinated Canadian neuromuscular clinical trial network to enhance trial readiness, capacity, and access in rare disease research.
Canadian-Led Phase II Studies Advance Vamorolone Evidence in Duchenne Muscular Dystrophy
NMD4C investigators contributed to two phase II studies evaluating vamorolone in boys with Duchenne muscular dystrophy across early childhood and adolescence, demonstrating safety, favorable pharmacokinetics, and potential efficacy. Led by Dr. Jean Mah and conducted across Canadian clinical trial sites with national and industry collaborators, the findings supported Health Canada approval of vamorolone as the first treatment for DMD in Canada. Leaders from both the clinical and patient advocacy communities, including Defeat Duchenne Canada, highlighted the impact of collaboration among patients, families, clinicians, and researchers in advancing care and improving access to new therapies.